Oncological outcomes and stoma-free survival following TaTME, a prospective cohort study
ConclusionsA local recurrence rate of 5.7% supports the oncological safety of TaTME for rectal cancer.
Source: Techniques in Coloproctology - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Eating Disorders & Weight Management | Endoscopy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Norway Health | Obesity | Radiology | Rectal Cancers | Study | Surgery | UK Health